 |
|
TREATMENT OF GOUT
CHARLEY J. SMYTH, M.D.;
ELSTON R. HUFFMAN, M.D.;
GEORGE M. WILSON, M.D.
AMA Arch Intern Med. 1956;97(6):783-792.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
RAPID progress has been made in recent years in the management of gout, one of man's oldest diseases. Today the patient with gouty arthritis can be effectively relieved during acute attacks and protected from recurrent bouts, and if tophi exist they can be reduced in size. This optimistic outlook depends, first, upon the physician's knowledge of the therapeutic measures available and, second, upon the patient's willingness to submit to uninterrupted life-time therapy.
Few illnesses follow such a set clinical pattern as does classical gout. Hench has described two stages—that characterized by recurrent episodes of acute joint inflammation followed by complete, but temporary, remissions (intercritical periods) and that of chronic gouty arthritis, or tophaceous gout.1 Because asymptomatic hyperuricemia (larval gout) precedes for some time attacks of acute joint symptoms, it is proposed that this part of the total disease be designated as the first stage of gout. For the purpose
. . . [Full Text PDF of this Article]
Author Affiliations
Denver
From the Department of Medicine, University of Colorado School of Medicine, and the Denver Veterans Administration Hospital.
Footnotes
Submitted for publication Feb. 1, 1956.
These studies were aided by grants from the United States Public Health Service, research number A-622c, and Geigy Pharmaceuticals, Division of Geigy Chemical Corporation, New York.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
